evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 1 · 16.7%High 3 · 50%

Nonavalent HPV vaccine vs quadrivalent HPV vaccine

High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 26‐year‐old females and males

Nonavalent HPV vaccine showed no clear difference in high‐grade cervical intraepithelial neoplasia, adenocarcinoma in… compared with quadrivalent HPV vaccine (high certainty).

1 finding from 1 review

Nonavalent HPV vaccine vs quadrivalent HPV vaccine

High‐grade cervical, vulval, and vaginal disease · 9‐ to 26‐year‐old females and males

Nonavalent HPV vaccine showed no clear difference in high‐grade cervical, vulval, and vaginal disease at up to 4.5‐year compared with quadrivalent HPV vaccine (high certainty).

1 finding from 1 review

Nonavalent HPV vaccine vs quadrivalent HPV vaccine

Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males

Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).

1 finding from 1 review

Nonavalent HPV vaccine vs quadrivalent HPV vaccine

Overall systemic events and general symptoms · 9‐ to 26‐year‐old females and males

Nonavalent HPV vaccine showed no clear difference in overall systemic events and general symptoms at 15‐day compared with quadrivalent HPV vaccine (moderate certainty).

1 finding from 1 review

Nonavalent HPV vaccine vs quadrivalent HPV vaccine

Serious adverse events at up to 4.5‐year · 9‐ to 26‐year‐old females and males

Nonavalent HPV vaccine showed no clear difference in serious adverse events at up to 4.5‐year compared with quadrivalent HPV vaccine (low certainty).

1 finding from 1 review